Investor Relations

Investor Relations

Invest in Quadrant Biosciences

We just launched the world’s first epigenetic saliva test for autism

Invest in Quadrant Biosciences

We just launched the world’s first epigenetic saliva test for autism

“Our goal is to facilitate diagnosis in younger children and maximize the potential for interventions to improve abilities, outcomes, and quality of life.”

-Rich Uhlig, Founder and CEO

Developed in medical research labs at SUNY Upstate Medical University and Penn State College of Medicine, the Clarifi™ diagnostic platform leverages new discoveries in epigenetics and the microbiome to provide first of its kind diagnostic solutions to many of today’s critical health care challenges. Clarifi ASD™, the first-ever biological diagnostic aid for autism spectrum disorder, has just launched commercially in the U.S.

“Our goal is to facilitate diagnosis in younger children and maximize the potential for interventions to improve abilities, outcomes, and quality of life.”

 

-Rich Uhlig, Founder and CEO

News room

SUNY implement biweekly testing to stem campus COVID-19 outbreaks

New York Post | September 2020

A rapid test designed to use a patient’s saliva to diagnose cases of COVID-19 is now available for use on SUNY campuses.

Saliva test for COVID-19 approved by NY Dept. of Health

WHAM | September 2020

A rapid test designed to use a patient’s saliva to diagnose cases of COVID-19 is now available for use on SUNY campuses.

Governor Cuomo Announces New Testing Initiatives to Improve COVID-19 Detection & Control Across New York State

NYS Governor’s Office | August 2020

Governor Andrew M. Cuomo today announced a series of new initiatives related to COVID-19 testing that will improve New York State’s ability to detect and control the virus in communities across the state.

University Scientists Selected to Implement COVID-19 Early Warning System in Upstate New York

SUNY ESF| August 2020

Game-changing approach will help inform decision-making, protect public health in Albany, Buffalo and Syracuse

New York State partners with Arcadis to pilot early detection of COVID-19 in wastewater

GlobeNewswire | August 2020

Game-changing approach will help inform decision-making, protect public health in upstate communities.

Groundbreaking autism test developed in CNY would diagnose children through saliva
CNY Central | December 2019

Traditionally, children who are thought to have autism are put through a seres of practical tests. About one in 59 children are diagnosed with Autism Spectrum Disorder in the United States according to the CDC.

Saliva test for autism hits market; Syracuse research could lead to faster help for kids
Syracuse | December 2019

A saliva test designed to quickly diagnose autism in toddlers has hit the market after seven years of research at SUNY Upstate Medical University and Penn State.

Microbes in Saliva May Offer Way of Detecting and Understanding Early Stages of Parkinson’s, Study Says
Parkinsons News Today | July 2019

A saliva test to detect oral microbes may offer an accurate way of detecting Parkinson’s in its early stages and further understanding of the disease, a study reports.

Quadrant Biosciences Recognized as New York Technology Business of the Year
Market Watch | May 2019

Quadrant Biosciences Inc. has been awarded the Technology Business of the Year by the New York State Small Business Development Center (SBDC).

Study finds correlation between specific epigenetic molecules and autism traits
BioSpace | April 2019

Scientists have discovered certain molecules in the saliva that not only differentiate children with autism spectrum disorder (ASD), but appear to correlate with specific autism traits.

Press releases

Quadrant Biosciences Wins $2.3M NIH Grant to Develop Saliva Test for Concussion - September 15, 2020
  Novel, minimally invasive biomarker to predict duration and character of concussions.

Quadrant Biosciences said on Monday that it has received a $2.3 million grant from the National Institutes of Health to develop its saliva-based microRNA diagnostic test for concussions in children and adolescents.

Renowned autism researcher Dr. Thomas Frazier joins Quadrant Biosciences Clinical Advisory Board - June 30, 2020
  Dr. Frazier will help guide research and clinical acceptance of the new Clarifi autism saliva test.

Dr. Frazier, a Professor of Psychology at John Carroll University, is one of the leading researchers in the field of autism.  Before joining the faculty at John Carroll, he was the Chief Science Officer for Autism Speaks, the largest autism advocacy organization in the United States.

Quadrant Biosciences Receives CPT® Proprietary Laboratory Analyses Code from the American Medical Association - April 21, 2020
Company That just Released World’s First Saliva Test for Autism Opens Up Investment Opportunity to the Public -
March 31, 2020
Quadrant Biosciences Inc, a leading developer of epigenetic diagnostic solutions, including the world’s first saliva test for autism, announced that it is now offering common shares of the company (at a price of $3/share, with a minimum investment of $300) through equity crowdfunding platform Wefunder.

The Reg A plus campaign is Quadrant’s first offering of common shares to the public — the company has previously raised over $32 million through private sales of its common shares to accredited investors only.

Quadrant Biosciences Launches First Ever Epigenetic Saliva Test for Autism - December 4, 2019
New Research shows link between Parkinson's disease and the microbiome - July 01, 2019
The oral microbiome may yield early biomarker for the disease.

A simple saliva swab may provide an accurate way of detecting Parkinson’s disease in its earliest stages, according to a study just published in the journal Plos One.

Quadrant Biosciences Recognized as New York Technology Business of the Year - May 7, 2019
Company’s Innovative Technology Recognized for its Social and Economic Impact

Quadrant Biosciences Inc. has been awarded the Technology Business of the Year by the New York State Small Business Development Center (SBDC).

Quadrant Biosciences Partners with Leading Edge Genomic Testing Company Admera Health - August 08, 2018
Rising companies in diagnostic space form strategic partnership.

Quadrant Biosciences Inc., an emerging life science company based in Syracuse, New York, is pleased to announce its strategic partnership with Admera Health, an advanced molecular diagnostics company headquartered in South Plainfield, NJ.

Wall Street Veteran Peter Cohen joins Quadrant Biosciences Board of Directors - April 24, 2018
Quadrant Biosciences Inc., a Syracuse, New York-based Life Science company, announced today that Wall Street veteran Peter Cohen will be joining its Board of Directors.

Mr. Cohen is currently Chairman of the Board of Cowen Inc., a well-known diversified financial services firm. Quadrant Bioscience, which focuses on the development of functional assessment and epigenetic biomarkers for various neurological conditions…

Published research

Validation of a Salivary RNA Test for Childhood Autism Spectrum Disorder
The oral microbiome of early stage Parkinson’s disease and its relationship with functional measures of motor and non-motor function
Parent Perspectives Towards Genetic and Epigenetic Testing for Autism Spectrum Disorder
Saliva MicroRNA Differentiates Children With Autism From Peers With Typical and Atypical Development
A Review of MicroRNA Biomarkers in Traumatic Brain Injury
Comparison of serum and saliva miRNAs for identification and characterization of mTBI in adult mixed martial arts fighters

Why invest in
Quadrant Biosciences?

World’s first saliva test for autism

We have just commercially launched Clarifi ASD, the world’s first saliva test for autism. Clarifi ASD is a novel epigenetic test that looks at small RNA molecules in the saliva, and can currently be accessed in clinics across 31 states.

Experienced management team

We have assembled a seasoned management team led by former Morgan Stanley Bank CEO Rich Uhlig, as well as an experienced medical advisory board comprising recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.

Global leaders in the development of epigenetic diagnostics

Clarifi ASD is just the beginning. Several other products based on our epigenetic diagnostic science are currently under development including saliva tests for concussion and Parkinson’s disease.

Successfully raised over $30 million

We have successfully raised over $30 million from private investors who believe in what we are doing; and we have received nearly $3 million in funding awards from the NIH* and others.

See what our
investors are saying

Who we are

Meet the team

We have assembled a seasoned management team, as well as an experienced medical advisory board comprising recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.

Our Board of Directors is composed of individuals with substantial knowledge and experience in the areas of finance, law, medicine, operations, intellectual property, and sales.

Our research partners

We are privileged to have partnered with a number of outstanding research universities and organizations to help further our epigenetic research.

International

We have entered into a research partnership with EU Aims – a Europe-wide collaboration between organizations representing autistic people and their families, academia and industry.

Quadrant Biosciences accomplishments

The science behind 
Clarifi ASD

Innovative technology

Clarifi ASD represents a new biological tool to aid in the diagnosis of autism. It is based on RNA rather than DNA. Epigenetics rather than genetics.

Specifically, Clarifi ASD measures the activity of genes by measuring specific RNAs and microbes in the saliva to provide a probability of an autism diagnosis.

Using state of the art next-generation sequencing, researchers at SUNY Upstate Medical University, Penn State College of Medicine and Quadrant Biosciences identified 32 features that comprise the Clarifi ASD panel.

Learn more about
Clarifi ASD

Investment opportunity

The science behind Clarifi

Early diagnosis: parent perspective

Product pipeline

Clarifi ASD is just the beginning.

Several other products based on the Clarifi Epigenetic Diagnostic Platform are currently under development including saliva tests for concussion and Parkinson’s disease.

Charitable involvement

Giving back

We support a number of organizations including Autism Nature Trail, PKAN research, Autism Speaks, Echo Autism, Autism Treatment Center, and Any Baby Can.

“As a company, we are committed to looking outside ourselves, and deploying our resources to assist other organizations and research efforts dedicated to improving the lives of people with autism and their families.”

-Rich Uhlig, Founder and CEO

“As a company, we are committed to looking outside ourselves, and deploying our resources to assist other organizations and research efforts dedicated to improving the lives of people with autism and their families.”

-Rich Uhlig, Founder and CEO

What are people saying